Argenx (NASDAQ:ARGX) is set to implement a leadership change in May, a development that UBS Global Research believes should ensure a smooth continuation of the company’s strategy and operations.

Tim Van Hauwermeiren to transition from CEO to Non-Executive Director and Chairman of Board of Directors and Karen Massey to transition from COO ...

Gilead Sciences promoted Keeley Wettan to EVP, general counsel, legal and compliance. She will join the senior leadership ...

Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter ...

Argenx (ARGX) announced on Tuesday that the U.S. FDA has granted priority review for its marketing application aimed at ...

Investors may be wondering whether argenx is still worth their attention after its strong run, or if the current share price ...

Argenx has announced that the US Food and Drug Administration has accepted for priority review a supplemental biologics ...

October 23, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...

In early January 2026, argenx reported preliminary full-year 2025 global product net sales of US$4.15 billion, outlined ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund rose 5.39% (Institutional ...

Argenx SE (NASDAQ: ARGX) on Monday announced it would discontinue the Phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with ...

(ENXTBR:ARGX) shares closed at €671.80, with recent moves likely catching the eye of investors watching biotech valuations.